Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Emad Uddin Abro"'
Autor:
Ing S Tiong, Devendra Hiwase, Emad Uddin Abro, Ashish Bajel, Emma Palfreyman, Sun Loo, Shaun Fleming, Chun Yew Fong, Tse-Chieh Teh, Adam Ivey, Andrew H Wei
Publikováno v:
Blood. 140:1453-1455
Autor:
Efstathios Kastritis, Jeffrey V. Matous, Emad Uddin Abro, P. Taylor Eves, Cheng Zheng, Tony Fiorino, Jesus Berdeja
Publikováno v:
Blood. 140:4438-4439
Autor:
Claire Hemmaway, Andrew H. Wei, Chung H. Kok, Nicola E. Potter, Richard Dillon, Ashish Bajel, Nigel H. Russell, Amanda F. Gilkes, James Anton Kuzich, Devendra K Hiwase, Adam Ivey, Jake Shortt, Abin Thomas, Emad Uddin Abro, Nisha Thiagarajah, James P Rowland, Matthew L. Smith, Kirsty Sharplin, Aditya Tedjaseputra, Carolyn S. Grove, Ing Soo Tiong
Monitoring of NPM1 mutant (NPM1mut) measurable residual disease (MRD) in acute myeloid leukemia (AML) has an established role in patients who are treated with intensive chemotherapy. The European LeukemiaNet has defined molecular persistence at low c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::286cfe6c9b290acbd9859864007fb26f
https://orca.cardiff.ac.uk/id/eprint/146658/1/advancesadv2021005455.pdf
https://orca.cardiff.ac.uk/id/eprint/146658/1/advancesadv2021005455.pdf
Autor:
Tara Cochrane, Jessica Pearce, Constantine S. Tam, Sumi Ratnasingam, Lourdes Calvente, Chan Yoon Cheah, Anna M. Johnston, Roopesh Kansara, Diego Villa, Stephen Bell, Maher K. Gandhi, Joshua W.D. Tobin, Michael MacManus, Eliza A Hawkes, David C. Hodgson, Melissa Liet Hing Ng, James Gallo, Emad Uddin Abro, Georgina Hodges, Jonathan Wong, Peter Mollee, Dipti Talaulikar, Robert Kridel, Nicholas Matigian, Kirk Morris, Katherine Colvin, Robert N Campbell, Chengetai Dunduru, Erica S Tsang, Sophie Shorten, Wojt Janowski, Kerry J. Savage, Xuan Tan, Michael Gilbertson, Gabrielle Rule, Greg Hapgood, Shao Yang Tneh
Publikováno v:
Blood Advances. 3:2804-2811
Management practices in early-stage (I/II) follicular lymphoma (FL) are variable and include radiation (RT), systemic therapy, or combined modality therapy (CMT). There is a paucity of data regarding maintenance rituximab in this cohort. We conducted
Autor:
Sarah Jane Halliday, Ken H. Young, Anthony J. Gill, Mark P. Hertzberg, Clare Gould, Gayathri Thillaiyampalam, William Stevenson, Simone Birch, Muhammed B. Sabdia, Xiaohong Tan, Zijun Y. Xu-Monette, Maher K. Gandhi, Lilia Merida de Long, Emad Uddin Abro, Annette Hernandez, Dipti Talaulikar, Sanjiv Jain, Robert Bird, Colm Keane, Joshua W.D. Tobin, Grace Gifford, Donna Cross, Soi Cheng Law, Sara Gabreilli
Publikováno v:
Blood advances. 4(7)
Blockade of the PD-1 axis has modest efficacy in diffuse large B-cell lymphoma (DLBCL), but data regarding LAG3 are sparse. The impact of LAG3 digital gene expression was tested in 309 patients with DLBCL treated with standard chemoimmunotherapy. Cel
Autor:
Adam Ivey, Emad Uddin Abro, Tse-Chieh Teh, Andrew H. Wei, Ing Soo Tiong, Shaun Fleming, Devendra K Hiwase, Emma Palfreyman, Sun Loo, Ashish Bajel, Chun Yew Fong
Publikováno v:
Blood. 138:1261-1261
Introduction Rising molecular measurable residual disease (MRD) is an arbiter of clinical relapse in acute myeloid leukemia (AML). Venetoclax (VEN) is active against IDH and NPM1 mutant (mt) AML as monotherapy (Konopleva et al, 2016 and Chua et al, 2
Autor:
Annette Hernadez, Clare Gould, Joshua W.D. Tobin, Sara Gabreilli, Santiyagu M. Savarimuthu Francis, Simone Birch, Soi Cheng Law, William Stevenson, Anthony J. Gill, Mark P. Hertzberg, Robert Bird, Emad Uddin Abro, Sanjiv Jain, Colm Keane, Dipti Talaulikar, Sarah-Jane Halliday, Donna Cross, Maher K. Gandhi, Grace Gifford
Publikováno v:
Blood. 132:1576-1576
LAG3 is an immune checkpoint expressed on a variety of immune cells including a sub-population of 'exhausted' effector T cells and TREGs. Early-phase studies of anti-LAG3 mAb show promise in solid and haematological cancers. We have previously demons
Autor:
Roopesh Kansara, Jessica Pearce, Constantine S. Tam, Melissa Liet Hing Ng, Jonathan Wong, Eliza A Hawkes, Diego Villa, Emad Uddin Abro, Dipti Talaulikar, Sophie Shorten, Chan Yoon Cheah, Jacob Darch, Lourdes Calvente, Xuan Tan, Anna Johnson, Michael Gilbertson, Greg Hapgood, James Gallo, Sumita Ratnasingam, Kerry J. Savage, Robert M. Campbell, Stephen Bell, Tara Cochrane, Shao Yang Tneh, David C. Hodgson, Gabrielle Rule, Georgina Hodges, Wojt Janowski, Robert Kridel, Katherine Colvin, Chengetai Dunduru, Joshua W.D. Tobin, Erica S Tsang, Maher K. Gandhi, Kirk Morris
Publikováno v:
Blood. 132:4148-4148
Background Stage I/II or early-stage follicular lymphoma (ESFL) is considered potentially curable with radiotherapy (XRT). While XRT does achieve local disease control in >90% of cases, more than half the patients (pts) relapse by 10 years (yr), gene
Autor:
Richard A. Anderson, Donna Cross, Joshua W.D. Tobin, Jay Gunawardana, Colm Keane, Simone Birch, Sarah-Jane Halliday, Judith Trotman, Muhammed B. Sabdia, Leanne Berkahn, Emad Uddin Abro, Annette Hernandez, Soi Cheng Law, Devinder Gill, Robert Bird, Anne L Saunderson, W P Law, Maher K. Gandhi, Peter Johnson, Michael J. Fulham
Publikováno v:
Blood. 132:1621-1621
In classical Hodgkin lymphoma (CHL) the tumor microenvironment (TME) is enriched in T cells that modulate antitumor immunity. PD1 blockade partially restores anti-tumoral T cell function, to induce impressive responses in a proportion of patients wit
Autor:
Peter Mollee, Maher K. Gandhi, Mohamed Shanavas, Emad Uddin Abro, Hyung Yoo, Frank Vari, Lynn Fink, Thanh Hoang, Joshua W.D. Tobin, Li Li, Jay Gunawardana, Ti Ma, Clare Gould, Santiyagu M. Savarimuthu Francis, Simone Birch, Valentine Murigneux, Colm Keane, Paul Anthony Scuffham, Nicholas Matigian
Publikováno v:
Blood. 130:728-728
Follicular Lymphoma (FL) is the most common indolent Non-Hodgkin Lymphoma. Despite generally favorable survival outcomes, 20% of FL patients experience 'Progression of Disease within 24 months' (POD24) and subsequently have poor long-term overall sur